The human herpesvirus 8 (HHV8/KSHV), along with certain other herpesviruses, encodes a gene with cyclin homology. Although the functional significance of the encoded cyclin is not clear at present, various lines of evidence propose a role for this cyclin in latently infected cells and possibly in the induction of tumors that arise in HHV8-infected individuals. We provide evidence here that the cyclin protein is expressed in HHV8 positive primary effusion lymphoma (PEL)-derived cell lines and that its level of expression varies greatly between different lines. Our analysis indicates that the level of cyclin protein expression in different PEL cell lines may correlate with the level of transcript expression during latency but not in cells induced to undergo lytic replication. In highly expressing BC-3 cells the cyclin is complexed with cdk6, cdk4, cdk2, and cdk5 under both latent and lytic conditions, although subtle changes in the level of cdk association are seen after induction of the lytic cycle. Altogether our findings support the notion that the cyclin is a latency-associated gene product expressed in PEL tumor cells. They furthermore indicate that after lytic cycle induction, the level of cyclin transcript expression may not be a reliable indicator for the level of cyclin protein expression.
INTRODUCTION
Kaposi's sarcoma herpesvirus or human herpesvirus 8 (KSHV/HHV8) is a member of the Rhadinovirus group of gamma herpesviruses. Infection by this virus is strongly implicated in the cause of hyperplastic and neoplastic diseases in humans. These are Kaposi's sarcoma (KS), an initially polyclonal hyperplasia of most likely endothelial origin; primary effusion lymphoma (PEL), a rare lymphoma arising concurrent with HIV infection; and a plasmablastic variant of Castleman's disease (MCD), an atypical polyclonal lymphoproliferative disorder with often fatal outcome.
Fragments of HHV8 DNA were initially discovered in KS tissue (Chang et al., 1994) . Since then, the presence of HHV8 sequences has been consistently found in KS tissues (Boshoff et al., 1995; de Lellis et al., 1995; Moore and Chang, 1995; Schalling et al., 1995) , PEL cells Nador et al., 1995) , and frequently in lymphocytes from Castleman's disease (Karcher and Alkan, 1995; Soulier et al., 1995) . Epidemiological evidence strongly suggests that HHV8 is instrumental in the development of all these types of disease, although other cofactors may also be involved, (reviewed in Chatlynne and Ablashi, 1999; Schulz, 1999) .
Like several other rhadinoviruses, HHV8 carries a number of genes of apparently cellular descent (Arvanitakis et al., 1996; Cesarman et al., 1996; Cheng et al., 1997; Gao et al., 1996; Murphy, 1997; Sarid et al., 1997;  reviewed in Moore and Chang, 1995; Neipel et al., 1997; Russo et al., 1996) . One of these is a protein with similarity to cellular D-type cyclins Chang et al., 1996; Godden-Kent et al., 1997; Li et al., 1997) . Cyclins are regulatory subunits that complex and activate cyclin dependent kinases (cdks) (reviewed in Pines, 1996) . Kinase activation by D-type cyclins is presumed to be a key requirement for entry of cells into S phase, and the deregulation of these kinases has been implicated repeatedly in human neoplasia (reviewed in Hall and Peters, 1996; Sherr, 1996) . Various lines of evidence suggest that the HHV8-encoded D-type cyclin (vcyc) can deter cellular growth control in many ways and, through this, may contribute to HHV8 inflicted malignancies. Experimental expression of vcyc in tissue culture systems demonstrated its ability to activate cellular cdks, resulting in a kinase resistant to cyclin-dependent kinase inhibitors (Swanton et al., 1997) and able to mediate phosphorylation and inactivation of the retinoblastoma protein , destabilization of the cyclin-dependent kinase inhibitor p27 KIP (Ellis et al., 1999; Mann et al., 1999) , and entry of cells into S phase in the absence of growth factors (Swanton et al., 1997) . These features suggest that expression of the vcyc protein may obstruct cell proliferation control and prevent cell cycle exit in response to extracellular cues. Through this, it may preserve the proliferation capacity of latently infected cells and at the same time augment HHV8-associated hyperplasia.
RNA encoding vcyc is found in latently infected PEL cells and in primary KS Cobo et al., 1999; Flore and Gao, 1997; Reed et al., 1998; Sturzl et al., 1999) . However, vcyc protein expression has not been demonstrated to date. In latently infected PEL cell lines, vcyc appears to be encoded by at least three different transcripts a major one of 2 kb (LT-2) and two minor ones of 6 kb (LT-1) and 1 kb (Dittmer et al., 1998; Sarid et al., 1997; Talbot et al., 1999) . Only LT-1 and LT-2 have been characterized in detail thus far. They derive from the same transcriptional start site, are generated by alternative splicing, and encompass reading frames for more than one gene. LT2 encodes ORF 72/vcyc as well as the adjacent reading frame for ORF K13/vFLIP. In addition to these, LT-1 encompasses sequences for the major latent antigen ORF73 (LANA). Although the presence of LANA protein has been amply demonstrated in KS tumours and PEL cells (Callahan et al., 1999; Couty et al., 1999; Gao et al., 1996; Katano et al., 1999; Rainbow et al., 1997) , it is not clear whether and to what extent the protein products vcyc or vFLIP are produced.
We generated anti-vcyc antibodies and used these to study vcyc expression in a number of different PEL cell lines. Our results indicate that the vcyc protein is present in these cells and is expressed during viral latency but that the level of vcyc expression varies greatly between different cell lines.
RESULTS
Cyclin antibody characterization and detection of vcyc in PEL cell lines.
We used recombinant full-length vcyc expressed as a glutathione-S-transferase (GST) fusion protein in Escherichia coli as an antigen to produce a rabbit serum as well as a monoclonal antibody with reactivity to vcyc. Both of these reagents specifically reacted in Western blots with recombinant vcyc produced by baculovirus but neither recognized cellular D-type cyclins produced in an identical manner (Fig. 1A) .
To address whether the cyclin protein is expressed in HHV8-infected PEL cells, we probed Western blots containing lysate from two different HHV8-positive PEL-derived cell lines, BC-3 (Arvanitakis et al., 1997) and BCP-1 (Boshoff et al., 1995) ; several HHV8 negative leukemia lines; and an EBV immortalized B cell line, LCL3 (Fig. 1B) . Both the rabbit serum and the monoclonal antibody recognized a protein in BC-3 of roughly 28 kDa, which was slightly smaller than the 9E10 tagged recombinant vcyc protein expressed in mammalian (Fig. 1B , top, lane 8) or insect cells (Fig. 1B, bottom, lane 8) . We note that the presence of the 9E10 tag attached to the amino-terminus of the recombinant cyclin proteins is expected to increase their size by approximately 2 kDa.
The 28-kDa protein detected in BC-3 lysate was not apparent in any of the other cell lines, including BCP-1, although this cell line has been reported to contain HHV8 DNA (Boshoff et al., 1995) and to express vcyc transcripts (Talbot et al., 1999) . Control blots using anti-tubulin antibody show that the absence of the prospective vcyc signal in BCP-1 and the HHV8-negative leukemia lines was not due to underloading of the lanes. A very similar signal was obtained throughout all lanes that contain cell lysates when the respective blots were counterprobed using anti-tubulin antibody (Fig. 1B) .
To confirm that the 28-kDa signal detected by the two different anti-vcyc reagents in BC-3 lysate is due to recognition of the same protein, we performed reciprocal immunoprecipitations followed by Western blots ( Figs.  2A and 2B ). We found that both the rabbit serum and the monoclonal antibody precipitate proteins of the correct size that are recognized by the reciprocal immunoreagent. This occurs under native conditions as well as . Blots were counterprobed with 9E10 antibody, recognising an amino-terminal tag present on all of the recombinant cyclins. vcyc denotes viral cyclin; cycD1, cycD2, and cycD3 denote human cyclins D1, D2, and D3; cdk4 and cdk6 denote expression of cyclin-dependent kinase subunits 6 and 4. Numbers on the left indicate the position of size markers. (B) Western blots containing lymphoma cell lysates were analysed using the cyclin antibodies. Lysate from transfected U2OS cells (lanes 7 and 8, top) or vcyc-expressing insect cells (lanes 7 and 8 bottom) were loaded as a positive control. Blots were counterprobed using anti-tubulin antibodies to demonstrate equal loading. Cell used were BCP-1 and BC-3 (HHV8 positive, PEL derived), LCL3 (EBV immortalised B cells), and Reh and Nalm-6 (pre-B lymphoblastoid leukemia derived). Use of antibodies was as in A. with lysate that had been denatured by boiling in SDS, indicating that the precipitated protein is recognized directly by the respective immunoreagent and is not precipitated by virtue of its association with another lysate component.
To confirm that the 28-kDa protein observed in BC-3 cell lysate is immunologically related to the vcyc protein, we performed Western blots in the presence of GSTvcyc antigen or uninfused GST as competitor (Fig. 2C) . Both the rabbit serum and the monoclonal antibody recognized the 28-kDa protein in BC-3 or the slightly larger vcyc protein expressed from recombinant baculovirus when uninfused GST was used as a competitor. In contrast, recognition of these antigens is either abolished or substantially reduced in the presence of GST-vcyc. Together, these experiments indicate that both reagents recognize the same 28-kDa protein in the BC-3 cell lysate and that this protein is antigenically related to the recombinant HHV8 cyclin, used as an immunogen.
The vcyc transcript levels in BC-3 and BCP-1
Our previous results indicated that the vcyc is avidly expressed in BC-3 cells but not, or to a vastly lower extent, in BCP-1 cells. In contrast, recent reports clearly demonstrate that vcyc encoding transcripts are present in BCP-1 cells (Talbot et al., 1999) . To confirm the presence of vcyc encoding transcripts in our BCP-1 cells and to investigate whether the difference in vcyc protein expression could be explained by different expression levels of vcyc encoding mRNA, we isolated polyadenylated RNA from both BC-3 and BCP-1 cells. Western blots of protein extracts prepared in parallel showed that the vcyc was clearly detectable in BC-3 but not in BCP-1 cells (Fig. 3A) . To accurately quantify the amount of vcyc encoding transcripts present in both cell lines, we performed RNA slot blots (Fig. 3B ). Using the ORF72/vcyc reading frame as a probe, a large difference in signal intensity became formamide-formaldehyde and blotted onto nylon membrane using a manifold multiblot apparatus. Blots were probed with a vcyc probe or a fragment of the cellular gene GAPDH. (BЈ) RT-PCR analysis. RNA from experiment 2 was reverse transcribed and amplified using cyclin primers. PCR products were separated by agarose gel electrophoresis, blotted onto membrane, and probed using the vcyc probe. RT denotes the presence or absence of reverse transcriptase in the reactions, respectively. (C) PhosphorImager-based quantification of the slot blot analysis shown in B. The vcyc values shown are normalised to GAPDH (vcyc/GAPDH).
FIG. 2.
Validation of the anti-vcyc immunoreactivity. (A and B) BC-3 lysate was precipitated using either the anti-vcyc monoclonal antibody 94B (94B) or the anti-vcyc rabbit serum [vcyc(R)]. The lysate was either used native (nat) or denatured by boiling in SDS (denat); buffer denotes omission of lysate and serves to control for background arising from the antibody-beads complexes. Precipitates were subjected to Western blot analysis and probed with the reciprocal immunoreagent. Lanes 1 and 2 contain input lysate of BC-3 and BCP-1. (C) Antigen competition. Western blots were produced using lysates as indicated and probed using the anti-vcyc reagents [94B; vcyc (R)] in the presence of either E. coli produced GST-cyclin fusion protein (GST-vcyc) or uninfused GST (GST) as a competitor; bv denotes use of baculovirus-directed insect cell lysate.
apparent between the two cell lines. In contrast, a probe detecting cell-encoded GAPDH transcripts yielded a very similar signal in both instances. PCR on reverse transcribed RNA (Fig. 3BЈ ) confirmed that the difference in vcyc signal was not due to contamination of our RNA preparation with viral DNA. The PCR signal obtained was strictly dependent on the use of reverse transcriptase, indicating the absence of viral DNA in the preparation. Together, these results suggest that although vcyc transcripts are clearly present in BCP-1 cells, their amount is significantly lower than in BC-3. Quantification by phosphorimaging shows that BCP-1 cells express in the order of sevenfold fewer vcyc encoding transcripts (Fig. 3C ). This relatively low vcyc transcript abundance could explain the absence of detectable vcyc protein expression in BCP-1 cells.
The vcyc protein expression after lytic cycle induction
Recent work, based on analysis of PEL-derived BC-1 cells, indicated that induction of lytic virus replication did not affect the level of vcyc transcript expression . In contast, other work, using BCP-1 or BCBL-1 cells, reported increased expression of the bicistronic vcyc encoding transcript, LT-2, and to a lesser extent the tricistronic transcript, LT1 (Dittmer et al., 1998; Talbot et al., 1999) . This could suggest that there exists a cell line-specific difference in the production of vcyc encoding transcripts, and possibly protein. More specifically, some PEL cell lines may express high levels of vcyc transcripts (and consequently, vcyc protein) during latency, whereas this expression in others may require induction of the lytic cycle. To address whether such differences may be responsible for the differences in vcyc transcript and protein levels, we extended our analysis to include BCP-1 and BC-3 cells exposed to TPA for 48 h. We found that TPA treatment of BCP-1 cells, in accordance with recently published observations (Talbot et al., 1999) , leads to a rise in vcyc encoding transcript levels (Figs. 4B and 4C). Quantification of the RNA slot blot signal indicates an increase of these transcripts by fivefold in comparison with mock-treated controls. However, despite this, expression of the vcyc protein was not detectable in TPA-treated BCP-1 cells.
Only a mild increase in vcyc transcript and no changes in vcyc protein levels were apparent on TPA treatment of BC-3 cells (Figs. 4A and 4B) . We note that vbcl2 transcripts were induced to the same level in BCP-1 and BC-3 cells, indicating that lytic induction has occurred in both cell types. Furthermore, RT-PCR analysis in the absence or presence of reverse transcriptase confirmed that as in the previous analysis, the RNA preparations were free of contaminating viral DNA.
Based on the above analysis (and in accordance with recently published observations), it would appear that vcyc encoding transcripts may indeed be induced in the course of lytic cycle induction in certain cell lines. However, even though the levels of vcyc transcripts on induction in BCP-1 approached levels comparable to those in BC-3, vcyc protein expression remained undetectable. This in turn indicates that transcripts accumulating during the lytic replication cycle in BCP-1 may not lead to a proportional increase in vcyc protein synthesis. It also indicates that vcyc transcript levels may not necessarily be a valid indicator as to the level and/or presence of vcyc protein expression. 
Biochemical features of the BC-3 expressed anti-vcyc reactive protein
To test whether the BC-3 protein has biochemical properties in accordance with those established previously for recombinant vcyc, we tested whether this protein copurified with cdk6, a kinase unit that is bound and activated by recombinant vcyc (Godden-Kent et al., 1997; Li et al., 1997; Swanton et al., 1997) . We found that the 28-kDa protein is precipitated with an anti-cdk6 antibody from native BC-3 cell lysate but not from lysate that had been heat-denatured before cdk6 precipitation (Fig. 5A) . We note that equal amounts of cdk6 are precipitated under native and denaturing conditions. These experiments indicate that the 28-kDa protein is in a complex with cellular cdk6 and thus shares functional features with recombinant vcyc.
To determine whether the majority or only a portion of the putative vcyc is complexed to cdk6, we depleted cdk6 from the BC-3 cell lysate using anti-cdk6 immunobeads (Fig. 5B) . Although this treatment resulted in removal of the majority of the cdk, the amount of vcyc remaining in the supernatant was barely altered, raising the possibility that the vast majority of vcyc protein in these cells is either free or in complexes with proteins other than cdk6 (Fig. 5B) . To assess the degree of free and complexed vcyc, BC-3 cell lysate was subjected to a gel filtration analysis followed by Western blotting (Fig. 5C ). This demonstrated that some of the protein indeed migrated with an apparent native size of 30 kDa (fraction 19) and thus is likely to be monomeric. A greater portion, however, migrated at a molecular size of greater than 100 kDa (fractions 16 and 17), which closely resembles the native size of cellular D-type-cdk complexes (Parry et al., 1999) , indicating that this portion of vcyc may be complexed to either cdks or other similar sized proteins.
Previous experiments using overexpression in COS monkey kidney cells indicated that vcyc can associate with other cdks apart from cdk6 (Godden-Kent et al., 1997; Li et al., 1997) . To address whether this is also the case for the authentic vcyc, we conducted immunoprecipitation experiments using antibodies against a range of other cdks. We found clear evidence for the existence of vcyc in complexes with cdk2, cdk4, and cdk5 (Fig. 5D ). No association with cdk1, cdk7, cdk8, or cdk9 could be demonstrated, although these cdk subunits were efficiently precipitated by their respective antibodies (data not shown). These experiments establish that the putative vcyc protein in BC-3 cell lysate can associate with a spectrum of cdks apart from cdk6. This spectrum is in accordance with predictions derived from previous experiments with recombinant vcyc protein (Godden-Kent et al., 1997; Li et al., 1997) . We note that these experiments do not allow conclusions as to the relative degree of association with the respective cdks or the contribution of these complexes to the overall activity. Neither of our anti-vcyc antibodies was able to precipitate a vcyccdk complex or an active kinase from BC-3 cell lysate or recombinant source, which precluded us from establishing these facts.
To address whether the cdk association changes as a result of lytic virus replication, we extended our analysis to BC-3 cells exposed to TPA for 48 h to induce lytic virus replication. We found that the same spectrum of cdks associated with the vcyc protein under both latent and lytic conditions. We note, however, that the degree of cdk4 association (and to a lesser extent, that with cdk5) increased in lytic cells. Densitometry of underexposed autoradiographs (not shown) indicates a threefold increase in the amount of vcyc present in anti-cdk4 precipitates and twice the amount in cdk5 precipitates in lytic (with TPA) versus mock-induced (without TPA) lysate. Increased association with theses cdks was consistently seen with independent lysate preparations. Similar amounts of the respective kinases were present in the precipitates (Fig. 5E, bottom) , and neither the overall amount of vcyc nor the amount of the respective cdks present in lysate changed significantly during lytic induction (not shown, also see Fig. 4 ). These results could indicate that critical changes in vcyc function occur during the lytic replication cycle.
The vcyc protein expression in other PEL-derived lines
To address whether the high level of vcyc protein expression is exceptional for BC-3 cells or is more widely seen in PEL lines, we analyzed a further four primary effusion lymphoma lines using Western blotting. Furthermore, to increase the chances of detecting low-level vcyc expression, we prepared all cell lysates fivefold more concentrated with respect to cell numbers. Analysis of these concentrated samples showed that only BC-3 cells expressed high amounts of the vcyc protein, yet under such conditions of increased sample loading, a faint signal at the correct molecular weight was apparent in all PEL-derived cell lines, including BCP-1, but absent in HHV8-negative LCL3 cells. Thus the HHV8 vcyc protein is expressed in BCP-1 and other PEL-derived cell lines, although at a significantly lower level.
To assess the relative degree of vcyc expression in the various PEL-derived cell lines, we repeated the Western analysis, including a serial dilution of the BC-3 cell lysate (Fig. 6C) . As before, a weak but significant signal was obtained from all PEL-derived cell lines. This signal was clearly weaker in intensity than that obtained with BC-3 lysate diluted ninefold. This indicates that all PEL cell lines analysed here express vcyc protein but that the amount of vcyc that accumulates in the majority of these cells is more than ninefold lower than that in BC-3 cells. . Native or denatured BC-3 lysates were immunoprecipitated using anti-cyclin-dependent kinase 6 (cdk6) antiserum. Immunoprecipitates were subjected to Western blot analysis and probed using anti-vcyc monoclonal antibody 94B (top panel). Subsequently, blots were counterprobed using anti-cdk6 (bottom panel). Lane 1 contains BC-3 input lysate; buffer denotes precipitation in the absence of cell lysate. (B) cdk6 depletion analysis. Lysates were depleted for cdk6 by two consecutive treatments with anti-cdk6 bound to Protein A-Sepharose. Western blots were conducted and analysed as in A. BC-3 denotes untreated lysates; Beads 1 and Beads 2 denote material recovered from the anti-cdk6-Sepharose after incubation with lysate; T0 denotes lysate before the addition of antibody; and T2 denotes lysate after two consecutive treatments with anti-cdk6. Note that lanes featuring beads were loaded using half the amount of material recovered, whereas only 1/10 of the total was loaded in lanes containing lysate. (C) Size fractionation of BC-3 cell lysates. BC-3 lysates were fractionated using gel filtration on Superdex 75. Fractions were subjected to Western blot analysis using 94B or a mixture of anti-cyclin D1, D2, and D3 antibodies. The size and position of gel filtration size markers are indicated on the top. (D) Spectrum of associated cdks. Native or denatured BC-3 lysates were immunoprecipitated using anti-cdk2, cdk4, and cdk5 antisera. All subsequent analysis was as described in A. (E) cdk association after induction of lytic virus replication. Cells were either treated with TPA for 48 h (ϩTPA) or with DMSO (ϪTPA) for an uninduced control. Analysis was essentially performed as outlined in A and D.
DISCUSSION
We demonstrate in this report that the HHV8-encoded cyclin protein is expressed in various cell lines derived from PEL. Various previous reports showed the presence of vcyc encoding transcripts in PEL lines and, furthermore, in KS biopsies Cobo et al., 1999; Dittmer et al., 1998; Flore and Gao, 1997; Rainbow et al., 1997; Reed et al., 1998; Sarid et al., 1997; Sturzl et al., 1999; Talbot et al., 1999) . More detailed analysis revealed that the bulk of these transcripts is polycistronic, encompassing, in addition to the cyclin reading frame, sequences derived for the neighbouring reading frames and leaving open whether any of these transcripts result in the translation and expression of the vcyc protein in these cells.
This would appear to be an issue of crucial importance. Experimental expression of recombinant vcyc protein in tissue culture cells repeatedly demonstrated that this cyclin, presumably via activation of the cellular cdk6 subunit and others, is able to override cell cycle regulatory mechanisms and in substantial ways can affect the growth properties of cells. These observations in turn led to the proposal that vcyc protein expression in cells latently infected with HHV8 could deter, via analogous mechanisms, cell proliferation control, thus positively influencing tumor formation consequential to HHV8 infection.
Missing links in support of such a notion are, first, whether not only transcripts but also vcyc protein is present in tumor cells and, second, whether this protein elicits biochemical features as predicted by the recombinant work. The work presented in this report provides answers to both of these questions. We provide evidence that vcyc protein is expressed in PEL-derived cell lines. Moreover, our experiments show that congruent with predictions from the recombinant work, this vcyc protein forms complexes with cdk6 and, furthermore, a spectrum of other cdks, including cdk5, cdk4, and cdk2 in these cells. These complexes are clearly seen in both latently infected BC-3 cells and after lytic cycle induction. Our analysis indicates that the abundance of certain complexes increases after treatment that triggers entry into the lytic virus cycle. We note that routine examination of TPA-treated BC-3 cells by immunofluorescence using antibodies against the late gene product K8.1 indicate that in accord with published results (Zhu et al., 1999) , only 12-15% of all these cells eventually become positive and thus may have supported virus replication successfully. Given the rather substantial (threefold) increase in cdk4 association with vcyc, this raises issues as to whether the changes concerned can possibly be confined and explained by this small number of cells undergoing viral replication. Our current ignorance as to vcyccdk complex stoichiometry does not allow us to make firm predictions in this regard.
Our analysis indicates that vcyc is expressed in five out of five PEL cell lines, although the level of vcyc protein expressed varies substantially between the different lines. Specifically, one of these cell lines, BC-3, expresses at least nine times more vcyc than any of the other lines examined. More subtle variations are seen between the remaining lines. Such different levels of vcyc protein expression may be explained, at least in part, by a different level of transcript expression as indicated by our analysis of RNA from high expressing BC-3 and low expressing BCP-1. However, we note that induction of virus replication in BCP-1 raised the vcyc transcript quantity to levels comparable to BC-3, yet did not result in a visible increase in vcyc protein expression. This observation suggests that additional, posttranscriptional mechanisms may exist in HHV8-infected cells that control the level of vcyc protein accumulation. Such controls could be exercised by expression of different transcript species with a different potential to translate the vcyc reading frame or rely on more sophisticated measures such as inhibition of ribosome entry or different protein stability.
Of more importance would seem to be whether the degree of vcyc protein expression has functional implications. As far as the cell encoded cyclins are concerned, current evidence suggests that not only their presence but also their finite level is of great significance (Roberts, 1999) . A mechanism that could explain such dose effects has been established in detail for the cellular D-type cyclins. A certain level of this group of cyclins would seem to be required to generate cyclincdk complexes that act as a reservoir for p27KIP inhibi- tors, which accumulate in resting and quiescent cells. Cyclin accumulation beyond a certain threshold, achieved via gene activation and through pathways involving growth factor receptor signaling and expression of the c-myc oncoprotein, is essential for the activation of cyclin E kinase and successful progression through the proliferation cycle (Bouchard et al., 1999; Cheng et al., 1998; Perez-Roger et al., 1999) .
However, it has been clearly demonstrated that p27KIP does not bind to cdk complexes formed by vcyc (reviewed in Swanton et al., 1997) . In turn, the resulting kinase activity may eliminate p27KIP via phosphorylation and destabilization, a catalytic operation that may eliminate the inhibitor even under conditions where the amount of cyclin-cdk complex is substoichiometric to that of p27KIP. It would, however, seem valid to conclude that a lower level of cyclin protein will translate into a lower level of kinase activation and thus a reduced rate of catalysis. Whether this is truly so and whether this could affect the growth characteristic of PEL cells or correlate with progression or prognosis of disease remains to be established.
MATERIALS AND METHODS

Cell culture
PEL-derived cell lines BC-3 (Arvanitakis et al., 1997) , HBL-6/BC-1 , ISI-1 (Oksenhendler et al., 1998) , BCBL-1 (Kedes and Ganem, 1997) , and BCP-1 (Boshoff et al., 1995) were obtained from E. Cesarman (Cornell University, NY), C. Boshoff (UCL, London, UK), F. Agbalika (Hopital Saint-Louis, Paris, France), and T. Schulz (University of Liverpool Medical School, UK). The EBV immortalized B cell line, LCL3 (Allday et al., 1995) , was a gift from P. Farrell (Ludwig Institute, St. Maries Branch, London, UK). The pre-B acute lymphoblastoid leukemia cell lines Reh and Nalm-6 were obtained from M. Greaves (LRF, London, UK).
All leukemia-derived cell lines were maintained in RPMI 1640 medium supplemented with 15% fetal calf serum. Lysates were prepared from actively growing cultures, freshly subcultured 36 h before harvest. To trigger lytic virus replication, freshly subcultured BC-3 and BCP-1 cells were treated with 20 ng/ml TPA. DMSO was used in place of the TPA for noninduced controls. Induction of the lytic cycle was confirmed by probing RNA, extracted in parallel from a portion of cells with a probe for the early lytic gene encoding ORF16 (vbcl2). U2-0S osteosarcoma cells were used for the transient expression of recombinant vcyc and maintained in Dulbecco's modified Eagle's medium. Transfection of vcyc expression constructs was as described (Ellis et al., 1999) . Insect cell culture and the production of recombinant protein by baculovirus have been described (Godden-Kent et al., 1997).
Antibodies and immunoreagents
Tag-specific anti-c-myc (9E10) antibody was purified from tissue culture supernatant using chromatography on DEAE-Sepharose. Antibodies against cdk1 (cdc2), cdk2, cdk5, cdk6, cdk7, cdk8, and cdk9 were purchased from Santa Cruz (Santa Cruz, CA). All were raised against C-terminal peptide epitopes of the respective kinases and chosen because of their known ability to precipitate endogenous cyclin-cdk complexes in an active form. Anti-tubulin monoclonal antibody was purchased from Sigma Chemical (Poole, Dorset, UK). Anti-rabbit and antimouse horseradish peroxidase-coupled secondary antibodies were obtained from Pierce Chemical (Rockford, IL).
Production of anti-cyclin antibodies
The coding region of vcyc was excised from pcDNA3 9E10 vcyc (Ellis et al., 1999) using EcoRI and subcloned into the pGex6P1 (Pharmacia Biotech, Uppsala, Sweden) to allow production of the cyclin fused to GST in E. coli. The vector was transformed into pLys bacteria, and the fusion protein was produced as described (Zarkowska and Mittnacht, 1997) with the following modifications. After binding of the fusion protein to glutathione-Sepharose beads, the beads were washed in 10 volumes of lysis buffer, and the bound fusion was eluted in 100 mM Tris-Cl, pH 8.0, 25 mM glutathione and subjected to chromatography on Mono Q to remove any uninfused GST protein. Rats and rabbits were injected with 50 mg of purified fusion protein. Subsequent boosts were performed at 4-week intervals. The production of rat monoclonal antibodies followed standard procedures (Harlow and Lane, 1988) . Rabbit serum was used unpurified. The anti-vcyc monoclonal antibody 94B was purified from hybridoma cell tissue culture supernatant by DEAESepharose chromatography.
Preparation of cell lysate, gel filtration, and immunoprocedures
Suspension cells were harvested by centrifugation, washed in PBS, and lysed at 1-5 ϫ 10 6 cells/ml in HB (25 mM HEPES, pH 7.0, 20 mM EDTA, 150 mM NaCl, including the protease inhibitors leupeptin, phenylmethylsulfonyl fluoride, and aprotinin). Lysates were stored at Ϫ70°C. Before use, cell debris was removed by centrifugation at 10,000 g. For Western blot analysis, samples were fractionated on 15% SDS-polyacrylamide gels. Proteins were transferred to PVDF membranes. Membranes were blocked and probed using 5% skim milk, 0.1% Tween 20 in Tris-buffered saline (TBS) for blocking and antibody dilutions. Antibody-antigen complexes were detected using enhanced chemiluminescence (ECL; Amersham International, Buckinghamshire, UK). For antigen competition experiments, primary antibodies were di-luted in blocking solution containing either purified GSTvcyc or uninfused GST and used for probing of the membrane after a 30-min preincubation period.
Size fractionation of BC-3 cell lysates were performed using a 2.4 ml of Superose 12 PC 3.2/30 column and the Smart automated protein fractionation minisystem (Pharmacia, Uppsala, Sweden). Then 50 l of cell lysate was loaded onto the column, and 30 fractions of 50 l each were collected. The column was calibrated using a native size marker set (Bio-Rad, Hercules, CA).
Immunoprecipitations and cdk depletion were performed essentially as described (Godden-Kent et al., 1997) . To produce denatured cell lysates, SDS was added to a final concentration of 5%, and the samples were heated to 95°C for 5 min. Before immunoprecipitation, the denatured lysates were diluted with 10 volumes of HB.
RNA preparation and analysis
RNA was extracted from PEL cells using the Microfast Track mRNA isolation kit (InVitrogen, La Jolla, CA) according to the manufacturer's instructions. Slot blot analysis was performed essentially as described (Sambrook et al., 1989) . Cloned sequences comprising the fulllength reading frame for ORF 72 (vcyc), ORF16 (vbcl2), and cellular glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were used as hybridisation probes. Probes were generated using the Rediprime II random prime labeling system (Amersham Pharmacia Biotech). Reverse transcription was performed using the cDNA Cycle Kit from InVitrogen. Primers used for the amplification of cyclin sequences were 5Ј-ATAGCTGTCCAG-GAATGCG-3Ј and 5Ј-GGCAACTGCCAATAACC-3Ј.
